Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the clinical outcomes of cancer patients treated with targeted therapies in the United States. The company's CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. It is developing CELx HSF test to diagnose two new sub-types of HER2-negative breast cancer. The company is also developing CELx MP test to diagnose 12 new potential cancer sub-types in breast, lung, colon, ovarian, kidney, and bladder cancers. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone763-392-0767
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees26
Next Earnings Date2/25/2020 (Estimated)
OptionableNot Optionable
Celcuity (NASDAQ:CELC) Frequently Asked Questions
What is Celcuity's stock symbol?
Celcuity trades on the NASDAQ under the ticker symbol "CELC."
How were Celcuity's earnings last quarter?
Celcuity Inc (NASDAQ:CELC) issued its quarterly earnings results on Thursday, November, 7th. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.02. View Celcuity's Earnings History.
When is Celcuity's next earnings date?
What price target have analysts set for CELC?
1 brokerages have issued twelve-month price targets for Celcuity's stock. Their forecasts range from $36.00 to $36.00. On average, they anticipate Celcuity's share price to reach $36.00 in the next year. This suggests a possible upside of 213.3% from the stock's current price. View Analyst Price Targets for Celcuity.
What is the consensus analysts' recommendation for Celcuity?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celcuity in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Celcuity.
Has Celcuity been receiving favorable news coverage?
Media stories about CELC stock have trended positive recently, InfoTrie reports. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Celcuity earned a coverage optimism score of 3.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Celcuity.
Are investors shorting Celcuity?
Celcuity saw a drop in short interest during the month of December. As of December 31st, there was short interest totalling 19,300 shares, a drop of 6.8% from the December 15th total of 20,700 shares. Based on an average daily trading volume, of 12,200 shares, the short-interest ratio is currently 1.6 days. Currently, 0.4% of the company's stock are short sold. View Celcuity's Current Options Chain.
Who are some of Celcuity's key competitors?
Some companies that are related to Celcuity include Personalis (PSNL), Centogene (CNTG), Fulgent Genetics (FLGT), DermTech (DMTK), Enzo Biochem (ENZ), Psychemedics (PMD), Miragen Therapeutics (MGEN), PotNetwork (POTN), Biocept (BIOC), Avant Diagnostics (AVDX), OpGen (OPGN), CBA Florida (CBAI), Cancer Genetics (CGIX), First Choice Healthcare Solutions (FCHS) and Aeon Global Health (AGHC).
What other stocks do shareholders of Celcuity own?
Who are Celcuity's key executives?
Celcuity's management team includes the folowing people:
- Mr. Brian F. Sullivan, Co-Founder, Chairman & CEO (Age 57)
- Dr. Lance G. Laing, Co-Founder, Chief Science Officer, VP, Sec. & Director (Age 57)
- Ms. Vicky Hahne, Chief Financial Officer (Age 53)
- Ms. Laura Beggrow RN, Chief Commercial Officer (Age 56)
- Mr. Larry Fitzgerald, VP of Strategic Partnerships & Managed Markets (Age 48)
When did Celcuity IPO?
(CELC) raised $18 million in an initial public offering on Wednesday, September 20th 2017. The company issued 2,000,000 shares at a price of $8.00-$10.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.
Who are Celcuity's major shareholders?
Which major investors are buying Celcuity stock?
How do I buy shares of Celcuity?
Shares of CELC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Celcuity's stock price today?
One share of CELC stock can currently be purchased for approximately $11.49.
How big of a company is Celcuity?
Celcuity has a market capitalization of $117.77 million. The company earns $-7,480,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. Celcuity employs 26 workers across the globe.View Additional Information About Celcuity.
What is Celcuity's official website?
How can I contact Celcuity?
Celcuity's mailing address is 16305 36TH AVENUE NORTH SUITE 100, MINNEAPOLIS MN, 55446. The company can be reached via phone at 763-392-0767.
MarketBeat Community Rating for Celcuity (NASDAQ CELC)
MarketBeat's community ratings are surveys of what our community members think about Celcuity and other stocks. Vote "Outperform" if you believe CELC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CELC will underperform the S&P 500 over the long term. You may vote once every thirty days.
